CA2686951C - Inhibiteurs de diacylglycerol acyltransferase - Google Patents

Inhibiteurs de diacylglycerol acyltransferase Download PDF

Info

Publication number
CA2686951C
CA2686951C CA2686951A CA2686951A CA2686951C CA 2686951 C CA2686951 C CA 2686951C CA 2686951 A CA2686951 A CA 2686951A CA 2686951 A CA2686951 A CA 2686951A CA 2686951 C CA2686951 C CA 2686951C
Authority
CA
Canada
Prior art keywords
phenyl
trifluoromethyl
amino
carbonyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2686951A
Other languages
English (en)
Other versions
CA2686951A1 (fr
Inventor
David Robert Bolin
Adrian Wai-Hing Cheung
Fariborz Firooznia
Matthew Michael Hamilton
Lee Apostle Mcdermott
Yimin Qian
Jenny Tan
Weiya Yun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madrigal Pharmaceuticals Inc
Original Assignee
Madrigal Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madrigal Pharmaceuticals Inc filed Critical Madrigal Pharmaceuticals Inc
Publication of CA2686951A1 publication Critical patent/CA2686951A1/fr
Application granted granted Critical
Publication of CA2686951C publication Critical patent/CA2686951C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2686951A 2007-05-22 2008-05-13 Inhibiteurs de diacylglycerol acyltransferase Expired - Fee Related CA2686951C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US93132707P 2007-05-22 2007-05-22
US93127307P 2007-05-22 2007-05-22
US93136907P 2007-05-22 2007-05-22
US93130307P 2007-05-22 2007-05-22
US60/931,327 2007-05-22
US60/931,303 2007-05-22
US60/931,273 2007-05-22
US60/931,369 2007-05-22
PCT/EP2008/055843 WO2008141976A1 (fr) 2007-05-22 2008-05-13 Inhibiteurs de diacylglycérol acyltransférase

Publications (2)

Publication Number Publication Date
CA2686951A1 CA2686951A1 (fr) 2008-11-27
CA2686951C true CA2686951C (fr) 2016-03-22

Family

ID=39619031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2686951A Expired - Fee Related CA2686951C (fr) 2007-05-22 2008-05-13 Inhibiteurs de diacylglycerol acyltransferase

Country Status (7)

Country Link
EP (1) EP2155687A1 (fr)
CN (1) CN101835757B (fr)
AU (1) AU2008253118B2 (fr)
BR (1) BRPI0811947A2 (fr)
CA (1) CA2686951C (fr)
MX (1) MX2009012285A (fr)
WO (1) WO2008141976A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007101A (es) 2004-12-14 2007-08-21 Astrazeneca Ab Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
AR058562A1 (es) 2005-12-22 2008-02-13 Astrazeneca Ab Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
WO2007126957A2 (fr) 2006-03-31 2007-11-08 Novartis Ag Nouveaux composés
BRPI0712802A2 (pt) 2006-05-30 2012-10-23 Astrazeneca Ab composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
US8153644B2 (en) 2007-05-22 2012-04-10 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) 2007-05-22 2012-02-14 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8058299B2 (en) 2007-05-22 2011-11-15 Via Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
AU2008258487B2 (en) 2007-06-08 2012-11-15 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
CA2687918C (fr) 2007-06-08 2016-11-08 Janssen Pharmaceutica N.V. Derives de piperidine/piperazine
EP2152271B1 (fr) 2007-06-08 2015-10-21 Janssen Pharmaceutica, N.V. Dérivés de piperidine/piperazine
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
JP5579170B2 (ja) * 2008-06-05 2014-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Dgat阻害剤とppar作動薬を含有する薬剤組み合わせ物
US8211884B2 (en) 2008-08-06 2012-07-03 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP2012509274A (ja) 2008-11-19 2012-04-19 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害薬
EP2367817A4 (fr) * 2008-12-03 2012-05-09 Via Pharmaceuticals Inc Inhibiteurs de l'enzyme diacylglycérol acyltransférase
US8211914B2 (en) 2008-12-17 2012-07-03 Madrigal Pharmaceuticals, Inc. Inhibitors of diacylglycerol acyltransferase
US8889674B2 (en) 2009-03-05 2014-11-18 Shionogi & Co., Ltd. Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism
WO2011078102A1 (fr) * 2009-12-22 2011-06-30 第一三共株式会社 Nouveau dérivé de phénoxypyrimidine
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
CN103237800B (zh) * 2010-10-14 2015-10-21 田边三菱制药株式会社 酰胺衍生物及其用途
TW201236685A (en) * 2010-11-11 2012-09-16 Daiichi Sankyo Co Ltd New pyrazole amide derivatives
US9458151B2 (en) * 2011-08-11 2016-10-04 Jikai Biosciences, Inc. Isothiazole derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
US9453003B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyrimidine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
CN102924444B (zh) * 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
US9452995B2 (en) * 2011-08-11 2016-09-27 Jikai Biosciences, Inc. Pyridine derivatives as PIM kinase inhibitors and preparation methods and use in medicinal manufacture thereof
WO2013154173A1 (fr) 2012-04-13 2013-10-17 田辺三菱製薬株式会社 Dérivé d'amidopyridine, et son utilisation
CN104710382A (zh) * 2015-02-10 2015-06-17 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104610187B (zh) * 2015-02-10 2016-04-06 佛山市赛维斯医药科技有限公司 一类含脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104592151A (zh) * 2015-02-10 2015-05-06 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构sglt2/sglt1双靶点抑制剂及用途
CN104592149A (zh) * 2015-02-10 2015-05-06 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104672166A (zh) * 2015-02-10 2015-06-03 佛山市赛维斯医药科技有限公司 一种含脒结构的腈基苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104672165B (zh) * 2015-02-10 2016-06-01 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的烷氧苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104610189A (zh) * 2015-02-10 2015-05-13 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途
CN104557765A (zh) * 2015-02-10 2015-04-29 佛山市赛维斯医药科技有限公司 一类含脒结构的卤代苯基噻唑羧酸酰胺类双靶点抑制剂、其制备方法及用途
CN104672164A (zh) * 2015-02-10 2015-06-03 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的sglt2/sglt1双靶点抑制剂、其制备方法及用途
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Taarのアゴニストとしての活性を有する5−エチル−4−メチル−ピラゾール−3−カルボキサミド誘導体
WO2019071073A1 (fr) 2017-10-06 2019-04-11 Forma Therapeutics, Inc. Inhibition de la peptidase 30 spécifique de l'ubiquitine
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
AU2019356011B2 (en) 2018-10-05 2025-02-06 Forma Therapeutics, Inc. Fused pyrrolines which act as Ubiquitin-Specific Protease 30 (USP30) inhibitors
JP2024501520A (ja) * 2020-12-22 2024-01-12 メルク・シャープ・アンド・ドーム・エルエルシー 新規ジアシルグリセリドo-アシルトランスフェラーゼ2阻害薬としてのテトラヒドロインダゾール誘導体の調製
AU2022297176A1 (en) 2021-06-25 2024-01-04 Korea Research Institute Of Chemical Technology Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4436129B2 (ja) * 2001-08-31 2010-03-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ジアリールシクロアルキル誘導体、その製造法及びppar−活性剤としてのその使用
WO2004022551A1 (fr) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Derive de furane ou de thiophene, et ses utilisations pharmaceutiques
EP1893592A1 (fr) * 2005-06-11 2008-03-05 AstraZeneca AB Dérivés d oxadiazole en tant qu inhibiteurs de la diacylglycérol acyltransférase (dgat)
EP1963313B1 (fr) * 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibiteurs de diacylglycérol acyltransférase (dgat)

Also Published As

Publication number Publication date
AU2008253118B2 (en) 2013-11-21
AU2008253118A1 (en) 2008-11-27
CA2686951A1 (fr) 2008-11-27
CN101835757B (zh) 2014-03-05
WO2008141976A1 (fr) 2008-11-27
BRPI0811947A2 (pt) 2014-11-11
EP2155687A1 (fr) 2010-02-24
MX2009012285A (es) 2009-12-15
CN101835757A (zh) 2010-09-15
HK1148519A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
CA2686951C (fr) Inhibiteurs de diacylglycerol acyltransferase
US8058299B2 (en) Diacylglycerol acyltransferase inhibitors
US8115011B2 (en) Diacylglycerol acyltransferase inhibitors
US8153644B2 (en) Diacylglycerol acyltransferase inhibitors
JP5076091B2 (ja) ジアシルグリセロールアシルトランスフェラーゼ(dgat)のインヒビター
US20090099201A1 (en) Diacylglycerol Acyltransferase Inhibitors
US8124766B2 (en) Inhibitors of diacylglycerol acyltransferase
US8211914B2 (en) Inhibitors of diacylglycerol acyltransferase
EP2197875A1 (fr) Inhibiteurs de la diacylglycérol acyltransférase
NZ587532A (en) Azetidine derivatives for inhibition of faah activity
US8211884B2 (en) Diacylglycerol acyltransferase inhibitors
CN101316844A (zh) 二酰甘油酰基转移酶(dgat)抑制剂
HK1148519B (en) Diacylglycerol acyltransferase inhibitors
HK1163446A (en) Inhibitors of diacylglycerol aclytransferase
HK1163071A (en) Inhibitors of diacylglycerol acyltransferase

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130513

MKLA Lapsed

Effective date: 20180514